Novel DAG-Lactone-Based Vav1 Inhibitors Show Anti-proliferative Activity in Pancreatic Cancer Models

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeting C1 domains is crucial for modulating signaling proteins in cancer.
• Atypical C1 domains, like that in Vav1, are underexplored therapeutic targets.
• Vav1 is a guanine nucleotide exchange factor critical in tumor development, including pancreatic cancer.

Purpose of the Study:

• To design and synthesize novel cationic diacylglycerol DAG-lactones.
• To evaluate the therapeutic potential of these compounds against Vav1-driven pancreatic cancer.
• To explore targeting atypical C1 domains for cancer therapy.

Main Methods:

• Synthesis of novel cationic diacylglycerol DAG-lactones.
• In vitro evaluation using cultured pancreatic tumor cells (Vav1-expressing and Vav1-negative).
• Assessment in patient-derived organoid models of pancreatic cancer.

Main Results:

• sn-1 cationic DAG-lactones selectively inhibited proliferation of Vav1-expressing pancreatic tumor cells.
• Vav1-negative cells showed no response to the treatment.
• Compounds demonstrated efficacy in inhibiting growth in patient-derived pancreatic cancer organoids.

Conclusions:

• Cationic DAG-lactones are effective regulators of atypical C1 domains, specifically Vav1.
• These compounds show translational value for pancreatic cancer patients with Vav1 expression.
• This work provides a foundation for targeting atypical C1 domain-containing proteins in cancer therapy.